Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years - XML Representation

Active as of 2022-05-28

Raw xml | Download



<EvidenceVariable xmlns="http://hl7.org/fhir">
  <id value="32143"/>
  <meta>
    <versionId value="13"/>
    <lastUpdated value="2023-12-06T21:24:16.455Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: EvidenceVariable</b><a name="32143"> </a><a name="hc32143"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceEvidenceVariable &quot;32143&quot; Version &quot;13&quot; Updated &quot;2023-12-06 21:24:16+0000&quot; </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-variable-definition.html">VariableDefinition</a></p></div><p><b>EvidenceVariableDefinition</b>: OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control</p><p><b>url</b>: <code>https://fevir.net/resources/EvidenceVariable/32143</code></p><p><b>identifier</b>: FEvIR Object Identifier/32143</p><p><b>version</b>: 1.0.0-ballot</p><p><b>name</b>: OutcomeVariable_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control_at_5_years</p><p><b>title</b>: OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years</p><p><b>status</b>: active</p><p><b>date</b>: 2022-05-28 12:16:43+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: The American Diabetes Association composite triple end point of hemoglobin A1c less than 7.0%, low-density lipoprotein cholesterol less than 100 mg/dL, and systolic blood pressure less than 130 mm Hg at 5 years</p><p><b>copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>author</b>: Brian S. Alper: </p><h3>RelatedArtifacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Citation</b></td></tr><tr><td style="display: none">*</td><td>cite-as</td><td>OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years [EvidenceVariable]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 32143. Revised 2022-05-28. Available at: https://fevir.net/resources/EvidenceVariable/32143. Computable resource at: https://fevir.net/resources/EvidenceVariable/32143.</td></tr></table><p><b>actual</b>: true</p><p><b>handling</b>: dichotomous</p></div>
  </text>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/evidence-variable-definition">
    <valueCodeableReference>
      <reference>🔗 
        <reference value="Group/172480"/>
        <type value="Group"/>
        <display
                 value="OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control"/>
      </reference>
    </valueCodeableReference>
  </extension>
  <url value="https://fevir.net/resources/EvidenceVariable/32143"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net"/>
    <value value="32143"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <version value="1.0.0-ballot"/>
  <name
        value="OutcomeVariable_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control_at_5_years"/>
  <title
         value="OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years"/>
  <status value="active"/>
  <date value="2022-05-28T12:16:43.370Z"/>
  <publisher value="HL7 International / Clinical Decision Support"/>
  <contact>
    <name value="HL7 International / Clinical Decision Support"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/dss"/>
    </telecom>
  </contact>
  <description
               value="The American Diabetes Association composite triple end point of hemoglobin A1c less than 7.0%, low-density lipoprotein cholesterol less than 100 mg/dL, and systolic blood pressure less than 130 mm Hg at 5 years"/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <author>
    <name value="Brian S. Alper"/>
  </author>
  <relatedArtifact>
    <type value="cite-as"/>
    <citation
              value="OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years [EvidenceVariable]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 32143. Revised 2022-05-28. Available at: https://fevir.net/resources/EvidenceVariable/32143. Computable resource at: https://fevir.net/resources/EvidenceVariable/32143."/>
  </relatedArtifact>
  <actual value="true"/>
  <handling value="dichotomous"/>
</EvidenceVariable>